两种治疗方案在晚期耐药性子宫内膜癌妇女中的疗效和安全性分析  

Efficacy and safety of fluorouracil and epirubicin in treating late-stage drug-resisting endometrial carcinoma: a comparative study

作　　者：郑旦 李岗[2] 范敏慧 ZHENG Dan;LI Gang;FAN Min-hui(Department of Pharmacy,Hangzhou Cancer Hospital,Hangzhou 310000,China;The First Department of the Tumor Surgery,Hangzhou Cancer Hospital,Hangzhou 310000,China)

机构地区：[1]杭州市肿瘤医院药剂科,浙江杭州310000 [2]杭州市肿瘤医院肿瘤外一科,浙江杭州310000

出　　处：《健康研究》2019年第2期208-211,共4页Health Research

摘　　要：目的探究表柔比星和氟尿嘧啶对晚期耐药性子宫内膜治疗效果和安全性差异。方法在医院接受治疗并已经产生耐药性的96例晚期子宫内膜癌患者,随机分为实验组和对照组各48例。对照组采用顺铂30 mg/m^2和氟尿嘧啶650 mg/m^2联合治疗,实验组采用顺铂30 mg/m^2和盐酸表柔比星40 mg/m^2联合治疗;均4周1个疗程,治疗两个疗程。检测患者卵巢癌抗原水平、血清脂联素、附睾蛋白4,观察两组治疗效果及药物不良反应情况。结果治疗后,两组患者癌抗原125(cancer antigen 125,CA125)、人附睾蛋白4(human epidiscript protein 4,HE4)、脂联素(adiponectin,APN)水平均显著改善,且实验组改善优于对照组;差异均有统计学意义(P<0.05)。实验组患者病情缓解者(68.75%)高于对照组(45.83%),总不良药物反应者(12.50%)低于对照组(31.25%),差异均有统计学意义(P<0.05)。结论表柔比星联合顺铂治疗晚期耐药性子宫内膜癌的效果和安全性均高于氟尿嘧啶。Objective To evaluate the efficacy and safety of epirubicin and fluorouracil in the treatment of drug-resisting endometrial carcinoma of stage IV. Method s Firstly, 96 hospitalized patients with advanced drug-resisting endometrial cancer were randomly divided into an experimental group ( n =48) and a control group ( n =48). The control group were subjected to treatment with cisplatin 30 mg/m 2 in combination with fluorouracil 650 mg/m 2 whereas the experimental group were treated with cisplatin 30 mg/m 2 in combination with epirubicin hydrochloride 40 mg/m 2 . Both groups were subjected to two courses of medication, each lasting 4 weeks. The ovarian cancer antigen level, serum adiponectin and epididymis protein 4 of the patients were then detected. The curative effect and adverse reactions of the two groups were lastly monitored. Results After treatment, the levels of cancer antigen 125 (CA125), human epidiscript protein 4 (HE4), and adiponectin (APN) in both groups were improved, with those of the experimental group being better than those of the control. The differences were statistically significant ( P <0.05).The rate of curative effectiveness in the experimental group (68.75%) was higher than that of the control group (45.83%). The rate of incidence of adverse reaction of the experimental group (12.50%) was lower than that of the control group (31.25%). The difference was statistically significant ( P <0.05). Conclusions The efficacy and safety of epirubicin combined with cisplatin in the treatment of advanced drug-resistant endometrial cancer are better than those of fluorouracil.

关 键 词：耐药性 子宫内膜癌 表柔比星 氟尿嘧啶 

分 类 号：R737.33[医药卫生—肿瘤]